<SEC-DOCUMENT>0001144204-17-031057.txt : 20170605
<SEC-HEADER>0001144204-17-031057.hdr.sgml : 20170605
<ACCEPTANCE-DATETIME>20170605171434
ACCESSION NUMBER:		0001144204-17-031057
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20170605
DATE AS OF CHANGE:		20170605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-218514
		FILM NUMBER:		17892094

	BUSINESS ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716
		BUSINESS PHONE:		617-244-1616

	MAIL ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>v468290_s3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; margin-left: 0.25in">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>As filed with the Securities and Exchange Commission on June 5, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact name of registrant as specified
in its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>04-3321804</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or other jurisdiction&nbsp;of</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>incorporation or organization)</I></P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(I.R.S. Employer</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Identification Number)</I></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>3301 Agriculture Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Madison, WI 53716</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(608) 441-8120</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Address, including
zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>James V. Caruso<BR>
President and Chief Executive Officer<BR>
3301 Agriculture Drive<BR>
Madison, WI 53716<BR>
(608) 441-8120 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Name, address, including zip code, and
telephone number, including area code, of agent for service)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<B>With a copy
to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<B>Gregory J.
Lynch, Esq.</B><BR>
<B>Michael Best &amp; Friedrich LLP</B><BR>
<B>One South Pinckney Street, Suite 700</B><BR>
<B>Madison, Wisconsin 53703</B><BR>
<B>(608)&nbsp;257-3501</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Approximate date of commencement of proposed sale to the
public</I>: From time to time after the effective date of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the only securities being registered on this Form are being
offered pursuant to dividend or interest reinvestment plans, please check the following box. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the securities being registered on this Form are to
be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered
only in connection with dividend or interest reinvestment plans, check the following box. <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to
Rule 462(e) under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this form is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of &ldquo;large accelerated
filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 19%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 28%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT><FONT STYLE="font-size: 10pt">(Do not check if a smaller reporting company)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards
provided pursuant to Section 7(a)(2)(B) of Securities Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Title of Each Class of <BR>
Securities to be Registered(1)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount to be<BR> Registered(1)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Proposed<BR> Maximum<BR> Offering<BR> Price Per<BR> Security(1)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Proposed<BR> Maximum<BR> Aggregate<BR> Offering<BR> Price(1)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount of<BR> Registration<BR> Fee(1)(4)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Common Stock, par value $0.00001 per share(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Preferred Stock, par value $0.00001 per share(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Units of the securities listed above</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Subscription Rights(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font-weight: bold">Total</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">50,000,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">5,795</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt">An indeterminate aggregate initial offering price or number of securities of each identified class is being registered as may from time to time be offered at indeterminate prices, with an aggregate initial offering price not to exceed $50,000,000.&nbsp;&nbsp;Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), there is also being registered such indeterminable number of additional shares of common stock, preferred stock, warrants, units and subscription rights as may be issued to prevent dilution resulting from share dividends, split-up, reverse split-up or similar events.&nbsp;&nbsp;Separate consideration may or may not be received for securities that are issuable on exercise, conversion or exchange of other securities or that are issued in unit.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt">Includes an indeterminate number of shares of common stock or preferred stock as may be sold from time to time at indeterminate prices or as may be issued upon conversion or exchange of preferred stock, warrants, units or subscription rights registered hereby.&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rights evidencing the right to purchase common stock or preferred stock.&nbsp;&nbsp;Pursuant to Rule&nbsp;457(g), no separate registration fee is payable with respect to the subscription rights being offered hereby since the subscription rights are being registered in the same registration statement as the securities to be offered pursuant thereto.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Calculated pursuant to Rule 457(o) under the Securities Act.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant hereby amends this registration statement
on such date or dates as may be necessary to delay its effective date until the registrant shall file&nbsp;a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of
the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities
and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"><B>The information in this prospectus is not complete
and may be changed. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities
in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>Subject to completion, dated
June 5, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="pg4img1_s3.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$50,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subscription Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Cellectar Biosciences, Inc. (&ldquo;we,&rdquo;
&ldquo;us&rdquo; or the &ldquo;Company&rdquo;) may from time to time offer to sell any combination of the securities described
in this prospectus, in one or more offerings. The aggregate initial offering price of all securities sold under this prospectus
will not exceed $50,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">This prospectus provides a general description
of the securities we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement
to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these
offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained
in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing
prospectus, as well as any documents incorporated by reference herein or therein before you invest in any securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><B>This prospectus may not be used to consummate
a sale of any securities unless accompanied by a prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Our common stock is traded on the Nasdaq
Capital Market under the symbol CLRB. On May 31, 2017, the last reported sale price for our common stock was $1.74 per share. The
aggregate market value of our outstanding common stock held by non-affiliates, or public float, as of the date of this prospectus
is approximately $27.7 million based on 12,773,385 shares of outstanding common stock held by non-affiliates, and a per share price
of $2.17, which was the last reported sale price of our common stock on the&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Nasdaq&nbsp;</FONT>Capital
Market on April 7, 2017 (a date within 60 days of the date hereof). Pursuant to General Instruction I.B.6 of Form S-3, in no event
will we sell securities registered on the registration statement of which this prospectus is a part in a public primary offering
with a value exceeding more than one-third of our public float in any 12-month period if our public float, measured in accordance
with such instruction, remains below $75.0 million. As of the date hereof, we have not offered any securities pursuant to General
Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus. The applicable
prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Capital Market or any securities
market or other exchange of the securities, if any, covered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">At no time will we issue shares of common
stock (whether upon conversion or exercise of warrants, preferred stock, units or subscription rights) in a transaction other than
a public offering if such transaction would result in the issuance of more than 19.999% of the amount of common stock issued and
outstanding for less than the greater of book or market value of the common stock unless (i) our stockholders have approved the
issuance of shares of common stock in excess of&nbsp;20%, or (ii) Nasdaq has provided a waiver of Listing Rule 5635(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may sell these securities directly to
investors, through agents designated from time to time or to or through underwriters or dealers. For additional information on
the methods of sale, you should refer to the section entitled &ldquo;Plan of Distribution&rdquo; in this prospectus. If any underwriters
are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such underwriters
and any applicable commissions or discounts will be set forth in a prospectus supplement. The price to the public of such securities
and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><B>Investing in our securities involves
a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 6.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.3pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2017.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 85%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">SUMMARY</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE&nbsp;REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6<FONT STYLE="font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">DESCRIPTION OF SECURITIES WE MAY OFFER</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">&nbsp;7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;10</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;11</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">DESCRIPTION OF SUBCRIPTION RIGHTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;11</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.8pt; text-indent: -8.8pt"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;15</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">This prospectus is a part of a registration
statement that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) utilizing a &ldquo;shelf&rdquo; registration
process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one
or more offerings up to a total dollar amount of $50,000,000. This prospectus provides you with a general description of the securities
we may offer. Each time we sell securities under this shelf registration, we will provide a prospectus supplement that will contain
specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided
to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing
prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus
or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable
prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as
described under the heading &ldquo;Where You Can Find Additional Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">You should rely only on the information
that we have provided or incorporated by reference in this prospectus, any applicable prospectus supplement and any related free
writing prospectus that we may authorize to be provided to you. We have not authorized any dealer, salesman or other person to
give any information or to make any representation other than those contained or incorporated by reference in this prospectus,
any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must
not rely upon any information or representation not contained or incorporated by reference in this prospectus, the accompanying
prospectus supplement or related free writing prospectus. We take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">This prospectus, the accompanying supplement
to this prospectus and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an
offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, the accompanying
supplement to this prospectus or any related free writing prospectus, if any, constitute an offer to sell or the solicitation of
an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such
jurisdiction. You should not assume that the information contained in this prospectus, any applicable prospectus supplement or
any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that
any information we have incorporated by reference therein is correct on any date subsequent to the date of the document incorporated
by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered
or the applicable securities are sold on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 3pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B><A NAME="a_002"></A>SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>This summary highlights selected information
from this prospectus and the documents incorporated herein by reference and does not contain all of the information that you need
to consider in making your investment decision. You should carefully read the entire prospectus, including the risks of investing
in our securities discussed under &ldquo;Risk Factors&rdquo; beginning on page&nbsp;6 of this prospectus, the information incorporated
herein by reference, including our financial statements, and the exhibits to the registration statement of which this prospectus
is a part. All references in this prospectus to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo;
and similar designations refer to Cellectar Biosciences, Inc. and its consolidated subsidiary, unless otherwise indicated or as
the context otherwise requires.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We are a clinical stage biopharmaceutical
company focused on the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Our
research and development program is based on its proprietary PDC cancer targeting delivery platform. The delivery platform possesses
the potential for the discovery and development of a broad range of cancer targeting agents. Our pipeline is comprised of pre-clinical
and clinical product candidates including radiotherapeutic and chemotherapeutic PDC&rsquo;s. The pipeline also includes diagnostic
and optical imaging assets. Our research and development resources are focused on the clinical advancement of its therapeutic PDC&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Our core company strategy is to leverage
our industry leading PDC, proprietary cancer targeting delivery platform to generate capital, supplement internal resources and
accelerate and broaden product candidate clinical development through strategic asset and research collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Our shares are listed on the Nasdaq Capital
Market under the symbol CLRB; prior to August 15, 2014, our shares were quoted on the OTCQX marketplace, and prior to February
12, 2014 were quoted under the symbol NVLT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Our PDC platform is based on our cancer-targeting
and delivery technology which provides selective delivery of a diverse range of oncologic payloads to cancer cells and cancer stem
cells. By linking various drug payloads to our proprietary phospholipid ether cancer-targeting vehicle, we believe we can create
PDCs with the potential to provide highly targeted delivery of chemotherapeutic and radiotherapeutic payloads to a broad range
of cancers. As a result, our PDC platform has the potential to improve the therapeutic index of drug payloads and enhancing or
maintaining efficacy while minimizing the off-target and toxic side effects that frequently occur with typical cancer therapies.
The Company is currently focused on the development of its lead therapeutic product candidate, CLR 131. Additionally, the Company
is executing the pre-clinical evaluation and development of its CLR CTX Chemotherapeutic PDC program with both internal and external
resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding: 6pt">CLR 131 is a small-molecule, cancer-targeting radiotherapeutic PDC that is designed to deliver cytotoxic (cell-killing) radiation
directly and selectively to cancer cells and cancer stem cells. CLR 131 is our lead therapeutic PDC product candidate and is currently
being evaluated in both Phase 1 and Phase 2 clinical studies. The Phase 1 clinical study is a standard three by three dose escalation
safety study in patients with relapse or refractory multiple myeloma. Multiple myeloma is the second most common hematologic cancer
and an incurable cancer of plasma cells. This cancer type was selected for clinical, regulatory and commercial rationales, including
multiple myeloma&rsquo;s highly radiosensitive nature, and continued unmet medical need in the relapse/refractory setting. The
primary goals of the Phase 1 study are to assess the compound&rsquo;s safety and tolerability in patients with relapsed or refractory
multiple myeloma. Secondary objectives includes establishment of a recommended Phase 2 dose, both with and without dexamethasone,
as well as an assessment of therapeutic activity, including surrogate efficacy markers, progression free survival (PFS) and overall
survival. The Investigational New Drug (IND) application was accepted by the U.S. Food and Drug Administration (FDA) in March 2014.
In December 2014, the FDA granted orphan drug designation for CLR 131 for the treatment of multiple myeloma. The Phase 1 study
was initiated in April 2015 and we announced favorable safety results from the first patient cohort in January 2016. The study&rsquo;s
Data Monitoring Committee (DMC), unanimously agreed to allow us to increase the dose of CLR 131 by 50% and advance into the second
cohort. The DMC reviewed Cohort 2 patient safety data in September 2016, and unanimously agreed to allow us to increase the dose
by 33% and advance to Cohort 3. In February 2017, the DMC unanimously determined the safety profile was again favorable in Cohort
3 and that it was acceptable to advance into Cohort 4 with an increase in dose by 20%. Surrogate markers of efficacy, including
M protein, Free Light Chain (FLC), Progression Free Survival (PFS), and Overall Survival (OS), are also captured as secondary objectives
of this Phase 1 study. In July 2016, the Company was awarded a $2,000,000 National Cancer Institute Fast-Track Small Business Innovation
Research (SBIR) grant to further advance CLR 131. The funds are supporting a Phase 2 study the Company initiated in March 2017
to further define the clinical benefits of CLR 131 in multiple myeloma and other rare hematologic malignancies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 3pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding: 6pt">The Company is exploring the creation of additional PDCs ranging from newly discovered to well-characterized chemotherapeutic
payloads under its CLR CTX Chemotherapeutic PDC program. The objective of our CTX program is to develop PDC chemotherapeutics through
conjugation of our delivery vehicle and non-targeted anti-cancer agents to improve therapeutic indices and expand potential indications
through the targeted delivery of chemotherapeutic payloads. Initial CTX product candidates include CLR 1601-PTX, CLR 1602-PTX and
CLR 1603-PTX; all are small-molecule, cancer-targeting chemotherapeutics in pre-clinical research. These PDCs are designed to selectively
deliver paclitaxel, a chemotherapeutic payload to cancer cells and cancer stem cells increasing the therapeutic index of paclitaxel
as a monotherapy. Each of our paclitaxel PDC&rsquo;s have been evaluated <I>in vitro</I> to demonstrate formulation stability and
CLR 1602-PTX is currently being studied <I>in vivo</I> to further explore the PDC&rsquo;s cancer targeting selectivity. In December
of 2015, the Company entered into a research collaboration for our PDC technology with Pierre Fabre laboratories, the third largest
French pharmaceutical company. The objective of the research collaboration is to co-design a library of PDC&rsquo;s employing Pierre
Fabre&rsquo;s chemotherapeutics in combination with our proprietary cancer targeting delivery vehicle. The newly developed PDC&rsquo;s
may provide enhanced therapeutic indices to otherwise highly potent, non-targeted payloads through the targeted delivery to cancer
cells provided by our cancer targeted delivery vehicle.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding: 6pt">CLR 125 is a cancer-targeting radiotherapeutic currently under pre-clinical investigation for the treatment of micrometastatic
disease. Similar to CLR 131, the selective uptake and retention of CLR 125 has been observed in malignant tissues during pre-clinical
studies. Preclinical evaluation of this molecule was completed in June 2016 as part of the Phase 1 portion of an NCI SBIR award
and demonstrated favorable biodistribution, tolerability, and dose response.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The Company&rsquo;s product pipeline also
includes a diagnostic imaging agent, CLR 124, a Phase 2-ready asset, as well as our 1500 series of optical imaging agents, including
1502, a Phase 1-ready asset. Although these are intriguing and potentially clinically useful compounds, at this time the Company
has prioritized the development of its therapeutic assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We believe our PDC platform has potential
to provide targeted delivery of a diverse range of oncologic payloads, as exemplified by the product candidates listed above, that
may result in improvements upon current standard of care (SOC) for the treatment of a broad range of human cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">For more information regarding the material
risks and uncertainties we face, please see &ldquo;Risk Factors&rdquo; beginning on page 6 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Our headquarters and manufacturing operation
is located at 3301 Agriculture Drive, Madison, Wisconsin 53716 and the telephone number at that address is (608) 441-8120. We maintain
a website at www.cellectar.com. The information included or referred to on, or accessible through, our website does not constitute
part of, and is not incorporated by reference into, this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 3pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Securities We May Offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may offer shares of our common stock
and preferred stock, various series of warrants to purchase any of such securities, either individually or in units and/or subscription
rights, from time to time under this prospectus, together with any applicable prospectus supplement and related free writing prospectus,
at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides you with a general
description of the securities we may offer. Each time we offer a type or series of securities, we will provide a prospectus supplement
that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">designation or classification;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">aggregate principal amount or aggregate offering price;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">rates and times of payment of dividends, if any;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">redemption, conversion or exchange terms, if any;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion
or exchange prices or rates and in the securities or other property receivable upon conversion or exchange;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">ranking;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">restrictive covenants, if any;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">voting or other rights, if any; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">important United States federal income tax considerations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">A prospectus supplement and any related
free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this
prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will
offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement
of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may sell the securities directly to
or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part
of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable
prospectus supplement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">the names of those underwriters or agents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">applicable fees, discounts and commissions to be paid to them;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">details regarding over-allotment options, if any; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 6pt"></TD><TD STYLE="width: 0.25in; padding: 6pt">&bull;</TD><TD STYLE="padding: 6pt">the net proceeds to us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may offer shares of our common stock,
par value $0.00001 per share, either alone or underlying other registered securities convertible into or exercisable for our common
stock. Holders of our common stock are entitled dividends as the Board of Directors of the Company (the &ldquo;Board&rdquo;) may
declare from time to time out of legally available funds, subject to the preferential rights of the holders of any shares of our
preferred stock that are outstanding or that we may issue in the future. Currently, we do not have any issued and outstanding preferred
stock. Each holder of our common stock is entitled to one vote per share. In this prospectus, we provide a general description
of, among other things, our dividend policy and the rights and restrictions that apply to holders of our common stock. Our common
stock is described in greater detail in this prospectus under &ldquo;Description of Capital Stock &mdash; Common Stock.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may issue shares of preferred stock,
par value $0.00001 per share, in one or more classes or series. Our Board or a committee designated by our Board will determine
the dividend, voting and conversion rights and other provisions at the time of sale. The particular terms of each class or series
of preferred stock, including redemption privileges, liquidation preferences, voting rights, dividend rights and/or conversion
rights, will be more fully described in the applicable prospectus supplement relating to the preferred stock offered thereby. Our
preferred stock is described in greater detail in this prospectus under &ldquo;Description of Capital Stock &mdash; Preferred Stock.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 6pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may from time to time offer warrants
for the purchase of our common stock and/or preferred stock in one or more series. We may issue warrants independently or together
with common stock and/or preferred, and the warrants may be attached to or separate from those securities. The warrants may be
evidenced by warrant certificates issued under one or more warrant agreements, which are contracts between us and an agent for
the holders of the warrants. In this prospectus, we have summarized certain general features of the warrants under &ldquo;Description
of Warrants.&rdquo; We urge you, however, to read the prospectus supplements and any free writing prospectus that we may authorize
to be provided to you related to the series of warrants being offered, as well as the complete warrant agreements and warrant certificates
that contain the terms of the warrants. Specific warrant agreements will contain additional important terms and provisions and
will be incorporated by reference as an exhibit to the registration statement which includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may offer units consisting of common
stock, preferred stock, and/or warrants to purchase any of such securities in one or more series. In this prospectus, we have summarized
certain general features of the units under &ldquo;Description of Units.&rdquo; We urge you, however, to read the prospectus supplements
and any free writing prospectus that we may authorize to be provided to you related to the series of units being offered, as well
as the unit agreements that contain the terms of the units. We will evidence each series of units by unit certificates that we
will issue under a separate agreement. We will enter into the unit agreements with a unit agent. Each unit agent will be a bank
or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement
relating to a particular series of units. The specific form of unit agreement and any supplemental agreements that describe the
terms of the series of units we are offering before the issuance of the related series of units will be incorporated by reference
as an exhibit to the registration statement which includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subscription Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may issue&nbsp;subscription rights&nbsp;to
purchase common stock, preferred stock or other securities described in this prospectus or any combination thereof. In this prospectus,
we have summarized certain general features of the units under &ldquo;Description of Subscription Rights.&rdquo; These&nbsp;subscription
rights&nbsp;may be issued independently or together with any other security offered by us and may or may not be transferable by
the securityholder receiving the subscription rights&nbsp;in such offering. In connection with any offering of&nbsp;subscription
rights, we may enter into a standby arrangement with one or more underwriters or other investors pursuant to which the underwriters
or other investors may be required to purchase any securities remaining unsubscribed for after such offering. The specific form
of subscription rights agreement and any supplemental agreements that describe the terms of the subscription rights we are offering
before the issuance of the related subscription rights will be incorporated by reference as an exhibit to the registration statement
which includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Investment in our securities involves a
high degree of risk. Prior to making a decision about investing in our securities, prospective investors should consider carefully
all of the information included and incorporated by reference or deemed to be incorporated by reference in this prospectus or the
applicable prospectus supplement, including the risk factors incorporated by reference herein from our Annual Report on Form 10-K
for the fiscal year ended December 31, 2016, as updated by annual, quarterly and other reports and documents we file with the SEC
after the date of this prospectus and that are incorporated by reference herein or in the applicable prospectus supplement. Each
of these risk factors could have a material adverse effect on our business, results of operations, financial position or cash flows,
which may result in the loss of all or part of your investment. For more information, see &ldquo;Where You Can Find Additional
Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">This prospectus and the documents incorporated
by reference herein contain, or will contain, &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the
Securities Act and Section 21E of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;), which include statements
that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements
of historical fact. These statements are based on our management&rsquo;s current beliefs, expectations and assumptions about future
events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements
may be found, among other places, in the Sections entitled &ldquo;Business,&rdquo; &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; incorporated by reference from our most recent
Annual Report on Form 10-K and in our Quarterly Reports on Form 10-Q, as well as any amendments thereto, filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">In some cases, you can identify forward-looking
statements by terminology, such as &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;may,&rdquo; &ldquo;should&rdquo;, &ldquo;could&rdquo;
or the negative of such terms or other similar expressions, but these are not the exclusive means of identifying forward-looking
statements. Forward-looking statements involve estimates, assumptions and uncertainties that could cause actual results to differ
materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors
discussed throughout this prospectus. Such statements are subject to various risks, uncertainties and assumptions that could cause
actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors
including, but not limited to, those set forth above under the section entitled &ldquo;Risk Factors&rdquo; in this prospectus and
any accompanying prospectus supplement. Given these risks, uncertainties and other factors, many of which are beyond our control,
you should not place undue reliance on these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Except as required by law, we assume no
obligation to update these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or
developments occurring after the date of this prospectus, even if new information becomes available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">U<FONT STYLE="font-family: Times New Roman, Times, Serif">nless
we specify otherwise in a prospectus supplement, we intend to use the net proceeds from our sale of the securities under this prospectus
for general corporate purposes, which may include making additions to our working capital, funding future acquisitions, or for
any other purpose we describe in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We have not yet determined the amount of
net proceeds to be used specifically for any of the foregoing purposes. Accordingly, our management will have broad discretion
over the uses of such proceeds. The specific allocations of the proceeds we receive from the sale of our securities will be described
in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>DESCRIPTION OF SECURITIES WE MAY OFFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may offer shares of our common stock
and preferred stock, various series of warrants to purchase any of such securities, either individually or in units and/or subscription
rights, from time to time under this prospectus, together with any applicable prospectus supplement and related free writing prospectus,
at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides you with a general
description of the securities we may offer. Each time we offer a type or series of securities, we will provide a prospectus supplement
that will describe the specific amounts, prices and other important terms of the securities. We may offer up to $50,000,000 of
securities under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The following description of our common
stock and preferred stock, together with any additional information we include in any applicable prospectus supplement or any applicable
free writing prospectus, summarizes the material terms and provisions of our common stock and the preferred stock that we may offer
under this prospectus. While the terms we have summarized below will apply generally to any future common stock or preferred stock
that we may offer, we will describe the particular terms of any class or series of these securities in more detail in the applicable
prospectus supplement. The following summary description of our common stock is based on the provisions of our Second Amended and
Restated Certificate of Incorporation, as amended, which we refer to as our certificate of incorporation, our by-laws, and the
applicable provisions of the Delaware General Corporation Law, which we refer to as the DGCL. This description may not contain
all of the information that is important to you and is subject to, and is qualified in its entirety by reference to our certificate
of incorporation, our by-laws and the applicable provisions of the DGCL. Our certificate of incorporation and our by-laws are incorporated
by reference into the registration statement of which this prospectus is a part or may be incorporated by reference in this prospectus
or any applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized and Outstanding Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Our authorized capital stock consists of
80,000,000 shares of common stock, $0.00001 par value per share and 7,000 shares of preferred stock, $0.00001 par value per share.
Our certificate of incorporation authorizes us to issue shares of our preferred stock from time to time in one or more series without
stockholder approval, each such series to have rights and preferences, including voting rights, dividend rights, conversion rights,
redemption privileges and liquidation preferences as our Board may determine. The rights of the holders of common stock will be
subject to, and may be adversely affected by, the rights of holders of any preferred stock that we may issue in the future. The
issuance of preferred stock, while providing desirable flexibility in connection with possible acquisitions and other corporate
purposes, could have the effect of making it more difficult for others to acquire, or of discouraging others from attempting to
acquire, a majority of our outstanding voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">As of May 31, 2017, we had 13,462,170 shares
of common stock outstanding and no shares of preferred stock outstanding. All outstanding shares of our common stock are duly authorized,
validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Voting</I>. Holders of our common stock
are entitled to one vote per share held of record on all matters to be voted upon by our stockholders. Our common stock does not
have cumulative voting rights. Persons who hold a majority of the outstanding common stock entitled to vote on the election of
directors can elect all of the directors who are eligible for election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Dividends</I>. Subject to preferences
that may be applicable to the holders of any outstanding shares of our preferred stock, the holders of our common stock are entitled
to receive such lawful dividends as may be declared by our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Liquidation and Dissolution</I>. In
the event of our liquidation, dissolution or winding up, and subject to the rights of the holders of any outstanding shares of
our preferred stock, the holders of shares of our common stock will be entitled to receive pro rata all of our remaining assets
available for distribution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Other Rights and Restrictions</I>. Our
certificate of incorporation prohibits us from granting preemptive rights to any of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">All of the outstanding shares of our common
stock are, and the shares of common stock issued upon the conversion of any securities convertible into our common stock will be,
fully paid and non-assessable. The shares of common stock offered by this prospectus or upon the conversion of any preferred stock
or exercise of any warrants offered pursuant to this prospectus, when issued and paid for, will also be, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Our common stock is listed on the Nasdaq
Capital Market under the symbol CLRB. The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We are authorized to issue 7,000 shares
of preferred stock, none of which were issued and outstanding as of May 31, 2017. Our Board is authorized, without action by our
stockholders, to classify or reclassify any unissued portion of our authorized shares of preferred stock to provide for the issuance
of shares of other classes or series, including preferred stock in one or more series. Our Board may fix or alter the dividend
rights, dividend rate, conversion rights, voting rights, rights and terms of redemption, the redemption price or prices, the liquidation
preferences of any wholly unissued series of Preferred Stock, and the number of shares constituting any such series and the designation
thereof, or any of them; and to increase or decrease the number of shares of any series subsequent to the issue of shares of that
series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be
so decreased, the shares constituting such decrease shall resume the status which they had prior to the adoption of the resolution
originally fixing the number of shares of such series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The particular terms of each class or series
of preferred stock that we may offer under this prospectus, including redemption privileges, liquidation preferences, voting rights,
dividend rights and/or conversion rights, will be more fully described in the applicable prospectus supplement relating to the
preferred stock offered thereby. The rights, preferences, privileges and restrictions of the preferred stock of each series will
be fixed by the certificate of designation relating to each series. We will incorporate by reference into the registration statement
of which this prospectus is a part the form of any certificate of designation that describes the terms of the series of preferred
stock we are offering before the issuance of the related series of preferred stock. The applicable prospectus supplement will specify
the terms of the series of preferred stock we may offer, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the distinctive designation and the maximum number of shares in the series;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the number of shares we are offering and purchase price per share;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the liquidation preference, if any;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the terms on which dividends, if any, will be paid;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the voting rights, if any, on the shares of the series;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the terms and conditions, if any, on which the shares of the series shall be convertible into, or exchangeable for, shares
of any other class or classes of capital stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the terms on which the shares may be redeemed, if at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any listing of the preferred stock on any securities exchange or market;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>a discussion of any material or special United States federal income tax considerations applicable to the preferred stock;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any or all other preferences, rights, restrictions, including restrictions on transferability, and qualifications of shares
of the series.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The issuance of preferred stock may delay,
deter or prevent a change in control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The description of preferred stock above
and the description of the terms of a particular series of preferred stock in any applicable prospectus supplement are not complete.
You should refer to the applicable certificate of designation for complete information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The DGCL provides that the holders of preferred
stock will have the right to vote separately as a class on any proposal involving fundamental changes in the rights of holders
of that preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate
of designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"><B>Possible Anti-Takeover Effects of Delaware Law and our Certificate of Incorporation and By-laws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Authorized but Unissued Stock</I>. We
have shares of common stock and preferred stock available for future issuance, in some cases without stockholder approval. We may
issue these additional shares for a variety of corporate purposes, including public offerings to raise additional capital, corporate
acquisitions, stock dividends on our capital stock or equity compensation plans. The existence of unissued and unreserved common
stock and preferred stock may enable our Board to issue shares to persons friendly to current management or to issue preferred
stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us, thereby protecting
the continuity of our management. In addition, if we issue preferred stock, the issuance could adversely affect the voting power
of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Amendments to By-laws</I>. Our certificate
of incorporation and by-laws authorize the Board to amend, repeal, alter or rescind the by-laws at any time without stockholder
approval. Allowing the Board to amend our by-laws without stockholder approval enhances Board control over our by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Classification of Board; Removal of
Directors; Vacancies. </I>Our certificate of incorporation provide for the division of the Board into three classes as nearly equal
in size as possible with staggered three-year terms; that directors may be removed only for cause by the affirmative vote of the
holders of two-thirds of our shares of capital stock entitled to vote; and that any vacancy on the Board, however occurring, including
a vacancy resulting from an enlargement of the Board, may be filled only by the vote of a majority of the directors then in office.
The limitations on the removal of directors and the filling of vacancies could have the effect of making it more difficult for
a third party to acquire, or of discouraging a third party from acquiring, control of us. Our certificate of incorporation requires
the affirmative vote of the holders of at least 75% of our shares of capital stock issued and outstanding and entitled to vote
to amend or repeal any of these provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Notice Periods for Stockholder Meetings</I>.
Our by-laws provide that for business to be brought by a stockholder before an annual meeting of stockholders, the stockholder
must give written notice to the corporation not less than 90 nor more than 120 days prior to the one year anniversary of the date
of the annual meeting of stockholders of the previous year; provided, however, that in the event that the annual meeting of stockholders
is called for a date that is not within 30 days before or after such anniversary date, notice by the stockholder must be received
not later than the close of business on the tenth day following the day on which the corporation's notice of the date of the meeting
is first given or made to the stockholders or disclosed to the general public, whichever occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Stockholder Action; Special Meetings</I>.
Our certificate of incorporation provides that stockholder action may not be taken by written action in lieu of a meeting and provides
special meetings of the stockholders may only be called by our president or by our Board. These provisions could have the effect
of delaying until the next stockholders' meeting stockholder actions that are favored by the holders of a majority of our outstanding
voting securities. These provisions may also discourage another person or entity from making a tender offer for our common stock,
because that person or entity, even if it acquired a majority of our outstanding voting securities, would be able to take action
as a stockholder only at a duly called stockholders' meeting, and not by written consent. Our certificate of incorporation requires
the affirmative vote of the holders of at least 75% of our shares of capital stock issued and outstanding and entitled to vote
to amend or repeal the provisions relating to prohibition on action by written consent and the calling of a special meeting of
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Nominations</I>. Our by-laws provide
that nominations for election of directors may be made only by (i) the Board or a committee appointed by the Board; or (ii) a stockholder
entitled to vote on director election, if the stockholder provides notice to the Secretary of the Corporation presented not less
than 90 days nor more than 120 days prior to the anniversary of the last annual meeting (subject to the limited exceptions set
forth in the by-laws). These provisions may deter takeovers by requiring that any stockholder wishing to conduct a proxy contest
have its position solidified well in advance of the meeting at which directors are to be elected and by providing the incumbent
Board with sufficient notice to allow them to put an election strategy in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Delaware Anti-Takeover Statute</I>.
We are subject to Section&nbsp;203 of the DGCL, an anti-takeover statute. In general, Section&nbsp;203 of the DGCL prohibits a
publicly held Delaware corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo;
for a period of three years following the time the person became an interested stockholder, unless the business combination or
the acquisition of shares that resulted in a stockholder becoming an interested stockholder is approved in a prescribed manner.
Generally, a &ldquo;business combination&rdquo; includes a merger, asset or stock sale, or other transaction resulting in a financial
benefit to the interested stockholder. Generally, an &ldquo;interested stockholder&rdquo; is a person who, together with affiliates
and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of
a corporation&rsquo;s voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect
to transactions not approved in advance by our Board, including discouraging attempts that might result in a premium over the market
price for the shares of common stock held by our stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The above provisions may deter a hostile
takeover or delay a change in control or management of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_008"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The following description, together with
the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the
material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase
common stock or preferred stock and may be issued in one or more series. Warrants may be offered independently or together with
common stock or preferred stock offered by any prospectus supplement, and may be attached to or separate from those securities.
While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will
describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement
and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the
terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus
or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We will issue the warrants under a warrant
agreement that we will enter into with a warrant agent to be selected by us. The warrant agent will act solely as an agent of ours
in connection with the warrants and will not act as an agent for the holders or beneficial owners of the warrants. We will file
as exhibits to the registration statement of which this prospectus is a part the form of warrant agreement, including a form of
warrant certificate that describes the terms of the particular series of warrants we are offering before the issuance of the related
series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and
qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to
a particular series of warrants. We urge you to read the applicable prospectus supplement and any applicable free writing prospectus
related to the particular series of warrants that we sell under this prospectus, as well as the complete warrant agreements and
warrant certificates that contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The applicable prospectus supplement will
specify the terms relating to a series of warrants, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the offering price and aggregate number of warrants offered;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued
with each such security or each principal amount of such security;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>if applicable, the date on and after which the warrants and the related securities will be separately transferable;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and
the price at which these shares may be purchased upon such exercise;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the terms of any rights to redeem or call the warrants;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the dates on which the right to exercise the warrants will commence and expire;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the manner in which the warrant agreements and warrants may be modified;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>United States federal income tax consequences of holding or exercising the warrants;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the terms of the securities issuable upon exercise of the warrants; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Before exercising their warrants, holders
of warrants to purchase common stock or preferred stock will not have any of the rights of holders of the securities purchasable
upon such exercise, including the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding
up or to exercise voting rights, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The following description, together with
the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the
material terms and provisions of the units that we may offer under this prospectus. While the terms we have summarized below will
apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series of units
in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ
from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this
prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We will file as exhibits to the registration
statement of which this prospectus is a part the form of unit agreement that describes the terms of the series of units we are
offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material
terms and provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit
agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus
supplements related to the particular series of units that we sell under this prospectus, as well as the complete unit agreement
and any supplemental agreements that contain the terms of the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may issue units comprised of one or
more shares of common stock, shares of preferred stock and warrants in any combination. Each unit will be issued so that the holder
of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations
of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included
in the unit may not be held or transferred separately, at any time or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We will describe in the applicable prospectus
supplement the terms of the series of units, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances
those securities may be held or transferred separately;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&bull;</TD><TD>any provisions of the governing unit agreement that differ from those described below; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&bull;</TD><TD>any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the
units.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The provisions described in this section,
as well as those described under &ldquo;Description of Capital Stock&rdquo; and &ldquo;Description of Warrants&rdquo; will apply
to each unit and to any common stock, preferred stock or warrant included in each unit, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_010"></A>DESCRIPTION OF SUBSCRIPTION RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The following description, together with
the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the
material terms and provisions of the subscription rights that we may offer under this prospectus. While the terms we have summarized
below will apply generally to any subscription rights that we may offer under this prospectus, we will describe the particular
terms of any series of subscription rights in more detail in the applicable prospectus supplement. The terms of any subscription
rights offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will
fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in
this prospectus at the time of its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We will file as exhibits to the registration
statement of which this prospectus is a part the form of subscription rights agreement that describes the terms of the series of
subscription rights we are offering, and any supplemental agreements, before the issuance of the related series of subscription
rights. The following summaries of material terms and provisions of the subscription rights are subject to, and qualified in their
entirety by reference to, all the provisions of the subscription rights agreement and any supplemental agreements applicable to
a particular series of subscription rights. We urge you to read the applicable prospectus supplements related to the particular
series of subscription rights that we sell under this prospectus, as well as the complete subscription rights agreement and any
supplemental agreements that contain the terms of the subscription rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may issue subscription rights to purchase
common stock, preferred stock or other securities described in this prospectus or any combination thereof. These subscription rights
may be issued independently or together with any other security offered by us and may or may not be transferable by the holder
receiving the subscription rights in such offering. In connection with any offering of subscription rights, we may enter into a
standby arrangement with one or more underwriters or other investors pursuant to which the underwriters or other investors may
be required to purchase any securities remaining unsubscribed for after such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">To the extent appropriate, the applicable
prospectus supplement will describe the specific terms of the subscription rights to purchase shares of our securities offered
thereby, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the date of determining the holders entitled to the rights distribution;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the price, if any, for the subscription rights;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the exercise price payable for the common stock, preferred stock or other securities upon the exercise of the subscription
right;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the number of subscription rights issued to each holder</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the amount of common stock, preferred stock, or other securities that may be purchased per each subscription right;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any provisions for adjustment of the amount of securities receivable upon exercise of the subscription rights or of the exercise
price of the subscription rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the extent to which the subscription rights are transferable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the date on which the right to exercise the subscription rights shall commence, and the date on which the subscription rights
shall expire;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the material terms of any standby underwriting or purchase arrangement entered into by us in connection with the offering of
subscription rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any applicable federal income tax considerations; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any other terms of the subscription rights, including the terms, procedures and limitations relating to the transferability,
exchange and exercise of the subscription rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may sell the securities being offered
hereby in one or more of the following ways from time to time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>through agents to the public or to investors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>to underwriters for resale to the public or to investors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>in &quot;at the market&quot; offerings, within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market
maker or into an existing trading market on an exchange or otherwise;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>directly to investors; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>through a combination of any of these methods of sale.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We will set forth in a prospectus
supplement the terms of the particular offering of securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the terms of the offering;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the name or names of any agents or underwriters;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the purchase price of the securities being offered and the proceeds we will receive from the sale;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any over-allotment options under which underwriters may purchase additional securities from us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any agency fees or underwriting discounts and other items constituting agents&rsquo; or underwriters&rsquo; compensation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any initial public offering price;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any discounts or concessions allowed or reallowed or paid to dealers; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>any securities exchanges or markets on which such securities may be listed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may issue to the holders of our common
stock on a pro rata basis for no consideration, subscription rights to purchase shares of our common stock or preferred stock.
These subscription rights may or may not be transferable by stockholders. The applicable prospectus supplement will describe the
specific terms of any offering of our common or preferred stock through the issuance of subscription rights, including the terms
of the subscription rights offering, the terms, procedures and limitations relating to the exchange and exercise of the subscription
rights and, if applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection
with the offering of common or preferred stock through the issuance of subscription rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may designate agents who agree to use
their reasonable efforts to solicit purchases of our securities for the period of their appointment or to sell our securities on
a continuing basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Underwriters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">If we use underwriters for a sale of securities,
the underwriters will acquire the securities for their own account. The underwriters may resell the securities in one or more transactions,
including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The obligations
of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement.
The underwriters will be obligated to purchase all the securities of the series offered if they purchase any of the securities
of that series. We may change from time to time any initial public offering price and any discounts or concessions the underwriters
allow or reallow or pay to dealers. We may use underwriters with whom we have a material relationship. We will describe the nature
of any such relationship in any prospectus supplement naming any such underwriter. Only underwriters we name in the prospectus
supplement are underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Direct Sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may also sell securities directly to
one or more purchasers without using underwriters or agents. Underwriters, dealers and agents that participate in the distribution
of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive from us and
any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act.
We will identify in the applicable prospectus supplement any underwriters, dealers or agents and will describe their compensation.
We may have agreements with the underwriters, dealers and agents to indemnify them against specified civil liabilities, including
liabilities under the Securities Act. Underwriters, dealers and agents may engage in transactions with or perform services for
us in the ordinary course of their businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Delayed Delivery Contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">If the prospectus supplement indicates,
we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities at
the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified
date in the future. The contracts would be subject only to those conditions described in the prospectus supplement. The applicable
prospectus supplement will describe the commission payable for solicitation of those contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Making, Stabilization and Other Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Unless the applicable prospectus supplement
states otherwise, each series of offered securities will be a new issue and will have no established trading market. We may elect
to list any series of offered securities on an exchange. Any underwriters that we use in the sale of offered securities may make
a market in such securities, but may discontinue such market making at any time without notice. Therefore, we cannot assure you
that the securities will have a liquid trading market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Any underwriter may also engage in stabilizing
transactions, syndicate covering transactions and penalty bids in accordance with Rule 104 under the Exchange Act. Stabilizing
transactions involve bids to purchase the underlying security in the open market for the purpose of pegging, fixing or maintaining
the price of the securities. Syndicate covering transactions involve purchases of the securities in the open market after the distribution
has been completed in order to cover syndicate short positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Penalty bids permit the underwriters to
reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased
in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions
and penalty bids may cause the price of the securities to be higher than it would be in the absence of the transactions. The underwriters
may, if they commence these transactions, discontinue them at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Passive Market Making</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Any underwriters who are qualified market
makers on the Nasdaq Capital Market may engage in passive market making transactions in the securities on the Nasdaq Capital Market
in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement
of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be
identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest
independent bid for such security. If all independent bids are lowered below the passive market maker&rsquo;s bid, however, the
passive market maker&rsquo;s bid must then be lowered when certain purchase limits are exceeded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Derivative Transactions and Hedging</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We, the underwriters or other agents may
engage in derivative transactions involving the securities. These derivatives may consist of short sale transactions and other
hedging activities. The underwriters or agents may acquire a long or short position in the securities, hold or resell securities
acquired and purchase options or futures on the securities and other derivative instruments with returns linked to or related to
changes in the price of the securities. In order to facilitate these derivative transactions, we may enter into security lending
or repurchase agreements with the underwriters or agents. The underwriters or agents may effect the derivative transactions through
sales of the securities to the public, including short sales, or by lending the securities in order to facilitate short sale transactions
by others. The underwriters or agents may also use the securities purchased or borrowed from us or others (or, in the case of derivatives,
securities received from us in settlement of those derivatives) to directly or indirectly settle sales of the securities or close
out any related open borrowings of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Electronic Auctions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We may also make sales through the Internet
or through other electronic means. Since we may from time to time elect to offer securities directly to the public, with or without
the involvement of agents, underwriters or dealers, utilizing the Internet or other forms of electronic bidding or ordering systems
for the pricing and allocation of such securities, you will want to pay particular attention to the description of that system
we will provide in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Such electronic system may allow bidders
to directly participate, through electronic access to an auction site, by submitting conditional offers to buy that are subject
to acceptance by us, and which may directly affect the price or other terms and conditions at which such securities are sold. These
bidding or ordering systems may present to each bidder, on a so-called &ldquo;real-time&rdquo; basis, relevant information to assist
in making a bid, such as the clearing spread at which the offering would be sold, based on the bids submitted, and whether a bidder&rsquo;s
individual bids would be accepted, prorated or rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Upon completion of such an electronic auction
process, securities will be allocated based on prices bid, terms of bid or other factors. The final offering price at which securities
would be sold and the allocation of securities among bidders would be based in whole or in part on the results of the Internet
or other electronic bidding process or auction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Agents, underwriters, and dealers may be
entitled, under agreements entered into with us, to indemnification by us against certain liabilities, including liabilities under
the Securities Act. Our agents, underwriters, and dealers, or their affiliates, may be customers of, engage in transactions with
or perform services for us, in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The maximum consideration or discount to
be received by any Financial Industry Regulatory Authority, or FINRA, member or independent broker dealer may not exceed 8.0% of
the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_012"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Michael Best &amp; Friedrich LLP, Madison,
Wisconsin will pass for us upon the validity of the securities being offered by this prospectus and applicable prospectus supplement,
and counsel named in the applicable prospectus supplement will pass upon legal matters for any underwriters, dealers or agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_013"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The audited financial statements incorporated
by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance
upon the report of Baker Tilly Virchow Krause, LLP, independent registered public accountants, upon the authority of said firm
as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. We have also filed a registration statement on Form S-3, including exhibits,
under the Securities Act with respect to the securities offered by this prospectus. This prospectus is part of the registration
statement, but does not contain all of the information included in the registration statement or the exhibits. You may read and
copy the registration statement and any other document that we file with the SEC at the SEC&rsquo;s Public Reference Room at 100
F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room.
Our SEC filings are also available to the public on the internet at a website maintained by the SEC located at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We disclose important information to you
by referring you to documents that we have previously filed with the SEC or documents that we will file with the SEC in the future.
The information incorporated by reference is considered to be part of this prospectus, and information in documents that we file
later with the SEC will automatically update and supersede information in this prospectus. We incorporate by reference the documents
listed below into this prospectus, and any future filings made by us with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of
the Exchange Act until the termination of this offering, including all filings made after the date of the initial registration
statement and prior to the effectiveness of the registration statement. We hereby incorporate by reference the following documents):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 15, 2017;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2017, filed with the SEC on May 11, 2017;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 25, 2017;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>our Current Report on Form 8-K, filed with the SEC on February 3, 2017;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>our Current Report on Form 8-K, filed with the SEC on April 11, 2017;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>our Current Report on Form 8-K, filed with the SEC on June 1, 2017; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the description of our securities contained in our Registration Statement on Form 8-A filed on August 14, 2014, including any
amendment or report filed for the purpose of updating such&nbsp; description.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.6pt">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">You should rely only on the information
contained in this prospectus, as updated and supplemented by any prospectus supplement, or that information to which this prospectus
or any prospectus supplement has referred you by reference. We have not authorized anyone to provide you with any additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Any statement contained in a document incorporated
or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to
the extent that a statement contained herein modifies or supersedes such statement. Any statement so modified or superseded shall
not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">You may request and obtain a copy of any
of the filings incorporated herein by reference, at no cost, by writing or telephoning us at the following address or phone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Cellectar Biosciences, Inc., 3301 Agriculture
Drive, Madison, WI 53716, Attention: Chief Financial Officer (608)&nbsp;441-8120.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$50,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subscription Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>May &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>14.</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Other Expenses of Issuance and Distribution</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The following table sets forth the various
expenses to be incurred in connection with the registration of the securities being registered hereby, all of which will be borne
by the registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">Securities and Exchange Commission registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,795</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer agent&rsquo;s and trustee&rsquo;s fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Printing and engraving expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0.25in">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-size: 10pt"> *</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="width: 99%"><FONT STYLE="font-size: 10pt">These fees cannot be estimated at this time, as they are calculated based on the securities offered and the number of issuances.&nbsp;&nbsp;An estimate of the aggregate expenses in connection with the sale and distribution of the securities being offered will be included in the applicable prospectus supplement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt"><B>15.</B></FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-size: 10pt"><B>Indemnification of Officers and Directors</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Section&nbsp;102 of the DGCL permits a
corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary
damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in
good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock
repurchase in violation of Delaware corporate law or obtained an improper personal benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Section&nbsp;145 of the DGCL provides that
a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving
at the request of the corporation in related capacities against expenses (including attorneys&rsquo; fees), judgments, fines and
amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to
which he is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner
he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of
the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have
been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court
determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly
and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">As permitted by the DGCL, our certificate
of incorporation and by-laws provide that: (i)&nbsp;we are required to indemnify our directors to the fullest extent permitted
by the DGCL; (ii)&nbsp;we may, in our discretion, indemnify our employees and agents as set forth in the DGCL; (iii)&nbsp;we are
required, upon satisfaction of certain conditions, to advance all expenses incurred by our directors and officers in connection
with certain legal proceedings; (iv)&nbsp;the rights conferred in the by-laws are not exclusive; and (v)&nbsp;we are authorized
to enter into indemnification agreements with our directors, officers, employees and agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the
foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;<B>16.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Exhibits</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">See Exhibit Index following the signature
page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt"><B>17.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Undertakings</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 23.1pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned
registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">(1) To file, during any period in which
offers or sales are being made, a post-effective amendment to this registration statement: (i)&nbsp;to include any prospectus required
by Section&nbsp;10(a)(3)&nbsp;of the Securities Act; (ii)&nbsp;to reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;), pursuant to Rule&nbsp;424(b)&nbsp;if,
in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price
set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and (iii)&nbsp;to
include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><I>Provided, however</I>, that paragraphs
(a)(1)(i), (a)(1)(ii)&nbsp;and (a)(1)(iii)&nbsp;do not apply if the registration statement is on Form S-3 or Form F-3 and the information
required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the
Commission by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of the Exchange Act, that are incorporated
by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;that
is part of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">(2) That, for the purpose of determining
any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I>
offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">(3) To remove from registration by means
of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">(4) That, for the purpose of determining
liability under the Securities Act to any purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">i. Each prospectus filed by
the registrant pursuant to Rule&nbsp;424(b)(3)&nbsp;shall be deemed to be part of the registration statement as of the date the
filed prospectus was deemed part of and included in the registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">ii. Each prospectus required
to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5)&nbsp;or (b)(7)&nbsp;as part of a registration statement in reliance on Rule&nbsp;430B
relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii)&nbsp;or (x)&nbsp;for the purpose of providing the information
required by Section&nbsp;10(a)&nbsp;of the Securities Act shall be deemed to be part of and included in the registration statement
as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale
of securities in the offering described in prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer and
any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which the prospectus relates, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof. <I>Provided, however</I> , that no statement made in a
registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated
by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">(5) That, for the purpose of determining
liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned
registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such
purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">i. Any preliminary prospectus
or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&nbsp;424;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">ii. Any free writing prospectus
relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">iii. The portion of any other
free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities
provided by or on behalf of an undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">iv. Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned
Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the
registrant&rsquo;s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where
applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Securities Exchange
Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial&nbsp;<I>bona
fide</I>&nbsp;offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned
registrant hereby undertakes to supplement the prospectus, after the expiration of the subscription period, to set forth the results
of the subscription offer, the transactions by the underwriters during the subscription period, the amount of unsubscribed securities
to be purchased by the underwriters, and the terms of any subsequent reoffering thereof. If any public offering by the underwriters
is to be made on terms differing from those set forth on the cover page of the prospectus, a post-effective amendment will be filed
to set forth the terms of such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the provisions set forth or described in Item 15 of this registration statement, or otherwise, the registrant
has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities
Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than
the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned
registrant hereby undertakes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant
pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Pursuant to the requirements of the Securities
Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in the City of Madison, State of Wisconsin, on June 5, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">CELLECTAR BIOSCIENCES, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ James V. Caruso</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">James V. Caruso</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints James V. Caruso and Chad J. Kolean as his true and lawful attorneys-in-fact and agents,
with full powers of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign
any and all amendments to this registration statement (including post-effective amendments and any related registration statements
filed pursuant to Rule 462 and otherwise), and to file the same with all exhibits thereto, and other documents in connection therewith,
with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents and full power and authority to do
and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and
purposes as he might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or any substitute
or resubstitute, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Pursuant to the requirements of the Securities Act of 1933,
as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 3%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ James V. Caruso</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">June 5, 2017</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">James V. Caruso</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(&nbsp;<I>principal executive officer</I>&nbsp;)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Chad J. Kolean</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">June 5, 2017</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chad J. Kolean</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(&nbsp;<I>principal financial officer and principal accounting officer</I>&nbsp;)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Stephen A. Hill</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">June 5, 2017</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Stephen A. Hill</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Stefan Loren</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">June 5, 2017</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Stefan Loren</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ John Neis</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">June 5, 2017</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">John Neis</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Frederick W. Driscoll</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">June 5, 2017</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Frederick W. Driscoll</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Douglas J. Swirsky</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">June 5, 2017</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Douglas J. Swirsky</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Incorporated by Reference</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom; width: 8%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT> <BR>
<FONT STYLE="font-size: 10pt"><B>No.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom; width: 60%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom; width: 8%"><FONT STYLE="font-size: 10pt"><B>Form</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom; width: 14%"><FONT STYLE="font-size: 10pt"><B>Filing Date</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom; width: 6%"><FONT STYLE="font-size: 10pt"><B>Exhibit<BR>
 No.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">1.1*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Underwriting Agreement (to be filed by amendment or as an exhibit to a report pursuant to Section 13(a), 13(c) or 15(d) of the Exchange Act)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Second Amended and Restated Certificate of Incorporation</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;April 11, 2011</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;3.1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certificate of Ownership and Merger of Cellectar Biosciences, Inc.&nbsp;&nbsp;with and into Novelos Therapeutics, Inc.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">February 11, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;3.1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certificate of Amendment to Second Amended and Restated Certificate of Incorporation</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;June 13, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;3.1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certificate of Amendment to Second Amended and Restated Certificate of Incorporation</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;June 19, 2015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;3.2</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certificate of Amendment to Second Amended and Restated Certificate of Incorporation</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;March 4, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;3.1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certificate of Amendment to Second Amended and Restated Certificate of Incorporation</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;June 1, 2017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;3.1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amended and Restated By-laws</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;June 1, 2011</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;3.1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of common stock certificate</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;S-1/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;November 9, 2011</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;4.1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.2*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of preferred stock certificate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.3*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Certificate of Designation with respect to Preferred Stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.4*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Warrant Agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.5*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Unit Agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.6*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Subscription Rights Agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">5.1**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Opinion of Michael Best &amp; Friedrich LLP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">23.1**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consent of Baker Tilly Virchow Krause,&nbsp;&nbsp;LLP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">23.2**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consent of Michael Best &amp; Friedrich LLP (included in Exhibit 5.1)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">24.1***</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Power of Attorney (included on the signature page to the registration statement)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font-size: 10pt">To be filed as an exhibit to a current report of the registrant on Form 8-K or other document to be incorporated herein by reference.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Included on the signature page to the registration statement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>v468290_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="width: 50%; padding: 0; text-align: left; font-size: 10pt; text-indent: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 50%; padding: 0; text-align: right; font-size: 10pt; text-indent: 0"><B>Michael Best &amp; Friedrich LLP</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; font-size: 10pt; text-indent: 0"><B>Attorneys at Law</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 5, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">VIA HAND DELIVERY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3301 Agriculture Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Madison, WI 53716</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acted as counsel to Cellectar Biosciences, Inc. (the
&quot;Company&quot;), a corporation organized under the laws of the State of Delaware, in connection with the preparation and filing
with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) of a registration statement on Form S-3 on the date
hereof, as amended from time to time (the &quot;Registration Statement&quot;), under the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registration Statement relates to the proposed issuance
and sale, from time to time, pursuant to Rule 415 under the Securities Act, as set forth in the Registration Statement, the prospectus
contained therein (the &ldquo;Prospectus&rdquo;) and the supplements to the prospectus referred to therein (each a &ldquo;Prospectus
Supplement&rdquo;), by the Company of up to an aggregate offering price of $50,000,000, or the equivalent thereof, of an indeterminate
number of securities consisting of the Company&rsquo;s common stock, $0.00001 par value per share (the &ldquo;Common Stock&rdquo;),
shares of the Company&rsquo;s preferred stock, $0.00001 par value per share (the &ldquo;Preferred Stock&rdquo;), warrants to purchase
any of the securities described above (the &ldquo;Warrants&rdquo;), units comprised of any combination of Common Stock, Preferred
Stock or Warrants (&ldquo;Units&rdquo;), and subscription rights to purchase Common Stock, Preferred Stock, Warrants or Units (&ldquo;Subscription
Rights,&rdquo; and together with Common Stock, Preferred Stock, Warrants and Units, the &ldquo;Securities&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with this opinion, we have examined and relied
upon originals, or copies certified to our satisfaction, of such records, documents, certificates, opinions, memoranda and other
instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. As to certain factual
matters, we have relied upon a certificate of an officer of the Company and have not independently sought to verify such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In rendering the opinions set forth herein, we have reviewed
originals or copies, certified or otherwise identified to our satisfaction, of such other documents, corporate records, instruments,
agreements, certificates and public records, and we have made such inquiries of the officers of the Company and have investigated
such matters of law as we deemed to be necessary to form a basis for the opinions expressed herein. We have relied upon and assumed:
(i) the genuineness of all signatures of persons signing all documents in connection with which this opinion is rendered; (ii)
the authenticity of all documents submitted to us as originals; (iii) the conformity to authenticated original documents of all
documents presented to us as certified, conformed, telefaxed or reproduced copies (iv) that the Registration Statement, and any
amendments thereto (including post-effective amendments), will have become effective under the Securities Act; (v) that a Prospectus
Supplement will have been filed with the Commission describing the Securities offered thereby; (vi) that the Securities will be
issued and the Securities will be sold in compliance with applicable U.S. federal and state securities laws and in the manner stated
in the Registration Statement and the applicable Prospectus Supplement; (vii) that a definitive purchase, underwriting, subscription,
placement agency or similar agreement with respect to any Securities offered will have been duly authorized and validly executed
and delivered by the Company and the other parties thereto; (viii) that any Securities issuable upon conversion, exchange, redemption
or exercise of any Securities being offered will be duly authorized, created and, if appropriate, reserved for issuance upon such
conversion, exchange, redemption or exercise; (ix) with respect to shares of Common Stock or Preferred Stock offered, that there
will be sufficient shares of Common Stock or Preferred Stock authorized under the Company&rsquo;s organizational documents that
are not otherwise reserved for issuance; and (x) the legal capacity of all natural persons. As to any facts material to the opinions
expressed herein that were not independently established or verified, we have relied upon oral or written statements and representations
of officers and other representatives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">michaelbest.com</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 5, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on such examination, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75pt"></TD><TD STYLE="width: 30.75pt">1.</TD><TD>With respect to shares of the Common Stock to be sold by the Company, when both: (a) the Board of Directors of the Company
or a duly constituted and acting committee thereof (such Board of Directors or committee being hereinafter referred to as the &ldquo;Board&rdquo;)
has taken all necessary corporate action to approve the issuance and the terms of the offering of the shares of Common Stock and
related matters; and (b) certificates representing the shares of Common Stock have been duly executed, countersigned, registered
and delivered either (i) in accordance with the applicable definitive purchase, underwriting, subscription, placement agency or
similar agreement approved by the Board, or upon the exercise of Warrants to purchase Common Stock, upon payment of the consideration
therefor (not less than the par value of the Common Stock) provided for therein or (ii) upon conversion or exercise of any other
Security, in accordance with the terms of such Security or the instrument governing such Security providing for such conversion
or exercise as approved by the Board, for the consideration approved by the Board, then the shares of Common Stock will be validly
issued, fully paid and nonassessable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75pt"></TD><TD STYLE="width: 30.75pt">2.</TD><TD>With respect to any particular series of shares of Preferred Stock, when both: (a) the Board has taken all necessary corporate
action to approve the issuance and terms of the shares of Preferred Stock, the terms of the offering thereof, and related matters;
and (b) certificates representing the shares of Preferred Stock have been duly executed, countersigned, registered and delivered
either (i) in accordance with the applicable definitive purchase, underwriting, subscription, placement agency or similar agreement
approved by the Board, or upon the exercise of Warrants to purchase Preferred Stock, upon payment of the consideration therefor
(not less than the par value of the Preferred Stock) provided for therein or (ii) upon conversion or exercise of such Security
or the instrument governing such Security providing for such conversion or exercise as approved by the Board, for the consideration
approved by the Board, then the shares of Preferred Stock will be validly issued, fully paid and nonassessable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 5, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75pt"></TD><TD STYLE="width: 30.75pt">3.</TD><TD>With respect to the Warrants, when both: (a) the Board has taken all necessary corporate action to approve the issuance and
terms of the Warrants and related matters; and (b) the Warrants have been duly executed and delivered against payment therefor,
pursuant to the applicable definitive purchase, underwriting, subscription, placement agency, warrant or similar agreement duly
authorized, executed and delivered by the Company and a warrant agent, and the certificates for the Warrants have been duly executed
and delivered by the Company and such warrant agent, then the Warrants will be validly issued and will constitute valid and binding
obligations of the Company, enforceable against the Company in accordance with their terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75pt"></TD><TD STYLE="width: 30.75pt">4.</TD><TD>With respect to the Units, when both: (a) the Board has taken all necessary corporate action to approve the issuance and terms
of the Units (including the Securities underlying the Units) and related matters; and (b) the Units (and the Securities underlying
the Units) have been duly executed and delivered against payment therefor, pursuant to the applicable definitive purchase, underwriting,
subscription, placement agency or similar agreement duly authorized, executed and delivered by the Company and any applicable unit
or other agents, and the certificates for the Units (including any Securities underlying the Units) have been duly executed and
delivered by the Company and any applicable unit or other agents, then the Units will be validly issued and will constitute valid
and binding obligations of the Company, enforceable against the Company in accordance with their terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75pt"></TD><TD STYLE="width: 30.75pt">5.</TD><TD>With respect to the Subscription Rights, when both: (a) the Board has taken all necessary corporate action to approve the issuance
and terms of the Subscription Rights (including the Securities underlying the Subscription Rights) and related matters; and (b)
the Subscription Rights (and the Securities underlying the Subscription Rights) have been duly executed and delivered against payment
therefor, pursuant to the applicable definitive purchase, underwriting, subscription, placement agency or similar agreement duly
authorized, executed and delivered in accordance with the terms thereof, then such Subscription Rights will constitute valid and
binding obligations of the Company, enforceable against the Company in accordance with their terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 5, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our opinion that any document is legal, valid and binding is
qualified as to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 31.5pt">a.</TD><TD>limitations imposed by bankruptcy, insolvency, reorganization, arrangement, fraudulent conveyance, moratorium or other laws
relating to or affecting the rights of creditors generally;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 31.5pt">b.</TD><TD>rights to indemnification and contribution, which may be limited by applicable law or equitable principles; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 31.5pt">c.</TD><TD>general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair dealing,
and the possible unavailability of specific performance or injunctive relief and limitation of rights of acceleration, regardless
of whether such enforceability is considered in a proceeding in equity or at law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We express no opinion as to the laws of any jurisdiction other
than the federal laws of the United States of America and the General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the filing of this opinion with the Commission
as Exhibit 5.1 to the Registration Statement. We also consent to the reference to our firm under the heading &ldquo;Legal Matters&rdquo;
in the Registration Statement. In giving such consent, we do not thereby concede that we are included in the category of persons
whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This opinion letter is given as of the date hereof, and we express
no opinion as to the effect of subsequent events or changes in law occurring or becoming effective after the date hereof. We assume
no obligation to update this opinion letter or otherwise advise you with respect to any facts or circumstances or changes in law
that may hereafter occur or come to our attention (even though the change may affect the legal conclusions stated in this opinion
letter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Michael Best &amp;
Friedrich LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">/s/ Michael Best &amp; Friedrich
LLP</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>v468290_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;<IMG SRC="bakertilly-logo.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Exhibit 23.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">We have issued our report dated March 15, 2017, with
respect to the consolidated financial statements of Cellectar Biosciences, Inc. and Subsidiary included in the Annual Report
on Form 10-K for the years ended December 31, 2016 and 2015, which is incorporated by reference in this Registration Statement
on Form S-3. We consent to the incorporation by reference of the aforementioned report in this Registration Statement, and
to the use of our name as it appears under the caption "Experts."</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">/s/ BAKER TILLY VIRCHOW KRAUSE, LLP</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="bakertilly-sig.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Madison, Wisconsin</P>

<P STYLE="margin: 0">June
5, 2017</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="bakertilly-footer.jpg" ALT=""></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pg4img1_s3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg4img1_s3.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 4P$M P$1  (1 0,1 ?_$ ,8   $#! ,!
M       ("0H! @,'! 8+!0$  00# 0$               ,$!08"!P@!"1
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M,0FX*W[79JFH^I#*B/9#47H <H>2W+#CCE2^N1U\+7^[B,J+PMH3[QBU9/\
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MW2B-'D[EOR:Y WG'S&7\Y9(O1R\N&*<"V?71*-XAN*LHU%1%K$,'#5@@VVU
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M%+4QQ$1.81,/?7.=RK:NZUJJZL65+69F?Y]'1&_;?2HM]&FD1B$C/+OCOP=
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M*A6GC_E^G1!'G;_S">7WN2O45O2UQ=G6A<.6=;%BQ*("'DMW3IJ6>F2D3 1
MIU';OXC=*[0UV1Z$TB;;M9:$)"M9G-6>)/9'(OK+<5U5X31X!N68SP]L:9]%
M/C=%\FO4$Q- W&S*_LW')'>5+F:KD!1H[_#'EJQ3%T0Q3IG3<2:I.A@H.W4O
MZJ7UZV;74&=(4L* [3(#CPG$=Z:VMNMOC=,[,LH*3/CU_"/2>;E!)#:!"DV
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MW-HV]B"U1NR871M<C965469@Y;G J*+LANE>@ZDK79GKJRZZTI*>4@*,^,^
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M';R]S?,*YD0!(AAVA6@ZB;Q36^G(987K")#5F#+B.V']GJ*Q]2UN A"B2!T
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M;E.A@$#%Z" ZMVXK,_>[JNY4[P2RM" !J \*0#@>L15K5?F+=1AA=.K6%J.
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MAB ! K2G7: ;A$!\:Z2N#:ZFB2I9.O X$P["$TJ.6W("70(M33:B%1*@(A\
M"()%-0*" #4*CIUR7O+(:5K,@#@2/?#0)IPX5U&@.\,!E%?IVI:CY3>@CU':
M0PB%?<%*CI&H??2@:DK&C(S/OZ>^,&Z2D!4IHHDO/ 8_E%/]T!3:2@5&M"?"
M'80&H!T[&'IVTNZA2&DU !U8'VP\!;2CE("?8(O%)F0-OD(]@_NB=:]JA0.H
MZS>#BV^:E2@>TQ@U3-CY"E'L'Y1:9!L(AN(CT#J()$"GLK0M '35CSH!7J43
MPQAF^Q1I= <"4HXX >^,R228%H3IXF$H=1Z ';H @(%#6:W%9U"%3Z8<MI:
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MA7:.?[GL_*<1?-[X4SE8+)W%VEE[&;M)I<",,]4(JXMZ?CW2:["YX!14!/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z ,4# 2(  A$! Q$!_\0
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MS8M:[W2?^07;_P"[_6N"M:[W2?\ D%V_^[_6N3)?]ZE_A_5'JO\ A(K>)O\
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A0>"/0CVI)J47<%JF?0-%%%8F84444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>bakertilly-logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bakertilly-logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ -D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HJ
M&ZN[>QM9+F[GC@@C&YY)&"JH]R:\HU_XY6MM<M!H>G_:T4X-Q.Q16_W5'./<
MX^E7"$I_"B)U(P^)GKM%>4>'OC%)K3_97TR&.^ ++&9]J3 #)"L?NL "<'(/
MJ.AWI/'&J2F-;?1;:#S.$>\U"- Q[ #JWX5G4?LWRR.K#8>>)ASTK->J7_!.
MYHKSEO'/B&'QSIVA2:9:3"ZC5YX(=WG6H)P2S;BI  W=!P1T[^C53323[G/?
MWG'L[!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5
M[R_L]/A,U[=06T0_CFD"#\S7%:]\7?#.D1,MI<'4KG'RQVWW<^[GC'TS]*[>
MZM+:]MV@N[>*XA;AHY4#J?J#Q6!/\/\ PK,#MT2RB)[QP+_(@BKCR?:(GSOX
M+'SSXK\<:SXNN=U]-Y=JIS':Q$B-?K_>/N?TKFZ^GH?A;X/BF\YM)65_^FDK
ME1_P$$+^E9OB;P;\/]#T.[N]0TZ&V1AE665P[.!PJ<^W0<5U1Q$%I%'#/"U'
M>4I'SQ;W$MI=17,#F.:%Q)&XZJP.0?SKV"7QAX8L+&&^MKQ?M-[%NFMDL87,
M!/4<*NY@<XW./4YZ'QJO0/!/PLU/Q,4O+_S+#2SR'9?WDH_V >W^T>/3-77I
MTY6E/H+"8BO2YH47\6YWO@KQSX*2\>WLTU"/4+MLS7=["'EN&]69"V![< >U
M>HJP90RD%2,@CO67H?AO2/#=H+?2K*.!<89P,N_^\W4UJUQ3:;NCOIJ2C:04
M445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9V
MJIJ\T7DZ5+:VS,.;F=3(4^B# /U)_ UQ5S\([;5[M;OQ!XAU34K@=3E8U]P%
MP=H]A7HU%5&;CL1*$9?$<QH_P\\+:&ZR6FDPO,IR)9\RL#ZC=D#\,5TQ4,I7
MG!&.#BEHI-MZLI1459(\6GU>Y@N_&L<GB+4()],E1=*C-VQ+,2_R;2?WF<*.
M02!7KVE/>2:19/J"JMZT"&X5>@DVC=C\<UY-H5_X8N?%7CJ#6;FS>VO+B,0A
MV!,F/,!\ON3R,8YZ5K:+KUYX.^$L$NMRF+461TL8+AL2')P@(/.!P>>@QTK:
M<;Z+R_(YZ<K-MOO^99B\6WJ_%!(IB1H=YYFGVK;OE:>+!9O;YF*>^!Z5U?BX
MR)X1U:XAFFAFM[26>*2&0HRNB%AR#R,CH>#7">)O!,UC\/H[JTUV]N)M*5;Z
M .8C'O'S,X(0,>K$98YXSFN@U#Q/I^N_"O4]2CN85\[395=-XRDK1D;#[YX'
MK2:3LUZ%*37,I>IE>'=2O_$OABPTG3M2NFO'CCGU/4S,6:WR=VQ#_?.,8Z 9
M)Y.#W4FG)%H\UJ+B\.4),QN7\S..H;.1TZ#CVKRG0M/N-.\+Z3XN\)%9[J&W
M6+5+",Y^TJO7CLXQ]3UYZ'T6R\7Z)J^@W&H07T2)#$6N(Y6"O!QR'4]#GCW[
M4IK70=.6GO;_ -?TSE/ \IUSPEIE_J7B:]COWNAN!O=HDVS<1E<_Q  8[YK6
M^)=Q=6&B6=[97MU:S_;(H289F4,C'D$=#]>M<M\.M5\*6_@K3X[UK-M6AN&9
M(@J_:&?S"4V]^>!Z=C6Y\8+NTB\+6EO<3JC2WT1";L,5&2Q&.< =_I5-?O+>
M9,9?NKWZ%D'4M$^).EZ59W]W=Z9>VLLMQ!=2F8P[<X<.V6 )VC!/?Z8[JO-;
MH'P-X@3Q#8>=?^'=1C2*[82-</;[<[7#DEBG)XSZ^PKT*ROK34;5+JRN8KB!
MQE9(G#*?Q%9S6S-(/=%"[T$7NJ/>R:GJ,68UC6&WN6CC4#)SM!P6)/7T KC?
M -M?>)_!$5_>:YJBWLDDBB5+E@!M;CY?3CFO1;BXAM+>2XN)4BAC4L[N<!1Z
MDUY]\&+VWF\"I:I*AG@GDWQ[AN )R#CTYIJ_(WZ"=N=+U_0L?%.]O=,TG2KJ
MPO;FUFDU".V<PRE0R,K$@CIG*CGK797EJKZ5+;++.@$6%D65@XP.#NSDGZGG
MO7 _&6ZMXM#T>*29%D&J12[2W.P*^6QZ#(KN[S4;.+19]0-S$;186?S@XV$8
MZYZ4->['YA%^_+Y'-?"^[NM2\$VVHWUW<75U</)O>:0MPKE0 .@X':F?$VXN
M['0;:[L+ZZM+@W<4)>"4KE6)!R.A^N*Y_P"&WC+0-'^'<$%[J4,=U;F4M;EO
MWC9=F 5>I)R.E:7QAU"WL_"EJ)'7SC?12)%GYF"Y)_#W]Q5.+]KMU(4U[&]^
MAW;V4;V!L_,N FW;O$SB3Z[\[L_C7":#K\_A;5]<T3Q-?SSF!3?6EW.Q)F@Q
M@@=LC'0=3FNIL/%NAZK>P6>FZC!>32JS[8'#%% Y+>G.!Z\UQ7Q3FTY/$W@T
MW,D*R1Z@K2[B,K#O3);T7COZ'WJ8*[Y674E9<R>QUOA&PU"/3SJ&K7%TUY>.
M\PMY9V9;9&.5C Z9 QR>>HSBNCIJ.LB*Z,&1AE64Y!'J*=4-W=S1*RL%%%%(
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>bakertilly-sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bakertilly-sig.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Q 3$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>bakertilly-footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bakertilly-footer.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H &4# 2(  A$! Q$!_\0
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H "\,6 #$COD 9I(--L[:?SX;=4DVA=P] ,#\@,?2BB@"U1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
